N-PHENYLARYLSULFONAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUND AS ACTIVE INGREDIENT, SYNTHETIC INTERMEDIATE FOR THE COMPOUND AND PROCESS FOR IT'S PREPARATION
申请人:NAGANAWA Atsushi
公开号:US20100041708A1
公开(公告)日:2010-02-18
An N-phenylarylsulfonylamide compound of formula (I)
(R
1
is COOH etc.; R
2
is hydrogen, methyl, etc.; R
3
and R
4
are a combination of methyl and methyl, etc.; R
5
is isopropyl etc.; Ar is thiazolyl, pyridyl, 5-methyl-2-furyl each optionally substituted with methyl; n is zero or 1), a synthetic intermediate for the compound and a process for its preparation. The compound of formula (I) binds to a prostaglandin E
2
receptor, especially an EP
1
subtype receptor, and antagonizes it. It is less affected by protein binding, so it has a satisfactory in vivo activity. Therefore, it is considered to be useful as an analgesic, an antipyretic agent, an agent for the treatment of pollakiuria (frequent urination) and/or lower urinary tract disease syndrome or an antineoplastic agent.
化合物(I)是一种N-苯基磺酰胺化合物,其化学式为(R1为COOH等;R2为氢,甲基等;R3和R4为甲基和甲基的组合等;R5为异丙基等;Ar为噻唑基,吡啶基,5-甲基-2-呋喃基,每个基团可选地被甲基取代;n为零或1),用于该化合物的合成中间体和其制备方法。化合物(I)与前列腺素E2受体结合,特别是EP1亚型受体,并拮抗其作用。它受蛋白结合的影响较小,因此具有令人满意的体内活性。因此,它被认为是一种有用的镇痛剂,退烧剂,用于治疗多尿和/或下尿路疾病综合症或抗肿瘤剂的药剂。